Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SR-01
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Eli Lilly
Deal Size : $40.0 million
Deal Type : Series C Financing
Seraxis Announced Closing of $40M Series C Financing Round
Details : Proceeds from the financing will primarily be used to complete the preclinical testing of SR-01, Seraxis’ lead cell therapy treatment for insulin-dependent diabetes and initiate first-in-human clinical trials.
Product Name : SR-01
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 02, 2021
Lead Product(s) : SR-01
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Eli Lilly
Deal Size : $40.0 million
Deal Type : Series C Financing